{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:03:52Z","timestamp":1791187432193,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T00:00:00Z","timestamp":1465257600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s00345-016-1871-x","type":"journal-article","created":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T11:54:39Z","timestamp":1465300479000},"page":"251-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC)"],"prefix":"10.1007","volume":"35","author":[{"given":"Francesco","family":"Soria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Haitel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitaly","family":"Margulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay D.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solene-Florence","family":"Kammerer-Jacquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Bensalah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"\u00d6zsoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesut","family":"Remzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian M.","family":"Gust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,7]]},"reference":[{"key":"1871_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21332","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2016. CA Cancer J Clin. doi: 10.3322\/caac.21332","journal-title":"CA Cancer J Clin"},{"key":"1871_CR2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.urology.2010.04.020","volume":"76","author":"R Abouassaly","year":"2010","unstructured":"Abouassaly R, Alibhai SMH, Shah N, Timilshina N, Fleshner N, Finelli A (2010) Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology 76:895\u2013901. doi: 10.1016\/j.urology.2010.04.020","journal-title":"Urology"},{"key":"1871_CR3","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.eururo.2015.06.044","volume":"68","author":"M Roupr\u00eat","year":"2015","unstructured":"Roupr\u00eat M, Babjuk M, Comp\u00e9rat E, Zigeuner R, Sylvester RJ, Burger M et al (2015) European Association of Urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol 68:868\u2013879. doi: 10.1016\/j.eururo.2015.06.044","journal-title":"Eur Urol"},{"key":"1871_CR4","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/cncr.24135","volume":"115","author":"V Margulis","year":"2009","unstructured":"Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E et al (2009) Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer 115:1224\u20131233. doi: 10.1002\/cncr.24135","journal-title":"Cancer"},{"key":"1871_CR5","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.eururo.2012.01.021","volume":"61","author":"EK Cha","year":"2012","unstructured":"Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS et al (2012) Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol 61:818\u2013825. doi: 10.1016\/j.eururo.2012.01.021","journal-title":"Eur Urol"},{"key":"1871_CR6","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/j.juro.2012.10.057","volume":"189","author":"M Roupr\u00eat","year":"2013","unstructured":"Roupr\u00eat M, Hupertan V, Seisen T, Colin P, Xylinas E, Yates DR et al (2013) Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. J Urol 189:1662\u20131669. doi: 10.1016\/j.juro.2012.10.057","journal-title":"J Urol"},{"key":"1871_CR7","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1002\/cncr.25122","volume":"116","author":"C Jeldres","year":"2010","unstructured":"Jeldres C, Sun M, Lughezzani G, Isbarn H, Shariat SF, Widmer H et al (2010) Highly predictive survival nomogram after upper urinary tract urothelial carcinoma. Cancer 116:3774\u20133784. doi: 10.1002\/cncr.25122","journal-title":"Cancer"},{"key":"1871_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/bju.12801","volume":"116","author":"I Lucca","year":"2015","unstructured":"Lucca I, Kassouf W, Kapoor A, Fairey A, Rendon RA, Izawa JI et al (2015) The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. BJU Int 116:72\u201378. doi: 10.1111\/bju.12801","journal-title":"BJU Int"},{"key":"1871_CR9","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.juro.2009.05.011","volume":"182","author":"NJ Hellenthal","year":"2009","unstructured":"Hellenthal NJ, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C et al (2009) Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the upper tract urothelial carcinoma collaboration. J Urol 182:900\u2013906. doi: 10.1016\/j.juro.2009.05.011","journal-title":"J Urol"},{"key":"1871_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/bju.12631","volume":"114","author":"T Seisen","year":"2014","unstructured":"Seisen T, Colin P, Hupertan V, Yates DR, Xylinas E, Nison L et al (2014) Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and\/or locally advanced upper tract urothelial carcinoma without metastasis. BJU Int 114:733\u2013740. doi: 10.1111\/bju.12631","journal-title":"BJU Int"},{"key":"1871_CR11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.eururo.2009.09.024","volume":"57","author":"H-M Fritsche","year":"2010","unstructured":"Fritsche H-M, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G et al (2010) Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 57:300\u2013309. doi: 10.1016\/j.eururo.2009.09.024","journal-title":"Eur Urol"},{"key":"1871_CR12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.eururo.2013.09.003","volume":"65","author":"E Xylinas","year":"2014","unstructured":"Xylinas E, Kluth L, Passoni N, Trinh Q-D, Rieken M, Lee RK et al (2014) Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool. Eur Urol 65:650\u2013658. doi: 10.1016\/j.eururo.2013.09.003","journal-title":"Eur Urol"},{"key":"1871_CR13","first-page":"699","volume":"7","author":"Y Sasaki","year":"2014","unstructured":"Sasaki Y, Sasaki T, Kawai T, Morikawa T, Matsusaka K, Kunita A et al (2014) HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients. Int J Clin Exp Pathol 7:699\u2013708","journal-title":"Int J Clin Exp Pathol"},{"issue":"Suppl 2","key":"1871_CR14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000055404","volume":"61","author":"S M\u00e9nard","year":"2001","unstructured":"M\u00e9nard S, Fortis S, Castiglioni F, Agresti R, Balsari A (2001) HER2 as a prognostic factor in breast cancer. Oncology 61(Suppl 2):67\u201372","journal-title":"Oncology"},{"key":"1871_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","volume":"34","author":"M Yan","year":"2015","unstructured":"Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R (2015) HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev 34:157\u2013164. doi: 10.1007\/s10555-015-9552-6","journal-title":"Cancer Metastasis Rev"},{"key":"1871_CR16","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S1470-2045(13)70477-7","volume":"15","author":"G Bianchini","year":"2014","unstructured":"Bianchini G, Gianni L (2014) The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol 15:e58\u2013e68. doi: 10.1016\/S1470-2045(13)70477-7","journal-title":"Lancet Oncol"},{"key":"1871_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y-J Bang","year":"2010","unstructured":"Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (London, England) 376:687\u2013697. doi: 10.1016\/S0140-6736(10)61121-X","journal-title":"Lancet (London, England)"},{"key":"1871_CR18","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/cam4.432","volume":"4","author":"J Bellmunt","year":"2015","unstructured":"Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M et al (2015) HER2 as a target in invasive urothelial carcinoma. Cancer Med 4:844\u2013852. doi: 10.1002\/cam4.432","journal-title":"Cancer Med"},{"key":"1871_CR19","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1111\/j.1464-410X.2009.09190.x","volume":"106","author":"C Bolenz","year":"2010","unstructured":"Bolenz C, Shariat SF, Karakiewicz PI, Ashfaq R, Ho R, Sagalowsky AI et al (2010) Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int 106:1216\u20131222. doi: 10.1111\/j.1464-410X.2009.09190.x","journal-title":"BJU Int"},{"key":"1871_CR20","doi-asserted-by":"publisher","first-page":"e27616","DOI":"10.1371\/journal.pone.0027616","volume":"6","author":"F Koga","year":"2011","unstructured":"Koga F, Yoshida S, Tatokoro M, Kawakami S, Fujii Y, Kumagai J et al (2011) ErbB2 and NF\u03baB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer. PLoS ONE 6:e27616. doi: 10.1371\/journal.pone.0027616","journal-title":"PLoS ONE"},{"key":"1871_CR21","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.juro.2015.05.087","volume":"194","author":"T Hayashi","year":"2015","unstructured":"Hayashi T, Seiler R, Oo HZ, J\u00e4ger W, Moskalev I, Awrey S et al (2015) Targeting HER2 with T-DM1, an antibody cytotoxic drug conjugate, is effective in HER2 over expressing bladder cancer. J Urol 194:1120\u20131131. doi: 10.1016\/j.juro.2015.05.087","journal-title":"J Urol"},{"key":"1871_CR22","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.urology.2005.06.117","volume":"66","author":"YS Tsai","year":"2005","unstructured":"Tsai YS, Tzai TS, Chow NH, Wu CL (2005) Frequency and clinicopathologic correlates of ErbB1, ErbB2, and ErbB3 immunoreactivity in urothelial tumors of upper urinary tract. Urology 66:1197\u20131202. doi: 10.1016\/j.urology.2005.06.117","journal-title":"Urology"},{"key":"1871_CR23","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1097\/PAI.0b013e318241cab9","volume":"66","author":"M Vershasselt-Crinquette","year":"2015","unstructured":"Vershasselt-Crinquette M, Colin P, Ouzzane A, Gnemmi V, Robin Y-M, Aubert S et al (2015) HER-2\/AKT expression in upper urinary tract urothelial carcinoma: prognostic implications. J Urol 66:2439\u20132445. doi: 10.1097\/PAI.0b013e318241cab9","journal-title":"J Urol"},{"key":"1871_CR24","first-page":"2439","volume":"30","author":"L Izquierdo","year":"2010","unstructured":"Izquierdo L, Truan D, Mengual L, Mallofre C, Alcaraz A (2010) HER-2\/AKT expression in upper urinary tract urothelial carcinoma: prognostic implications. Anticancer Res 30:2439\u20132445","journal-title":"Anticancer Res"},{"key":"1871_CR25","doi-asserted-by":"publisher","unstructured":"Sobin LH, Gospodarowicz MK, Wittekind Ch (2009) TNM classification of malignant tumours, vol 10. doi: 10.1016\/S0936-6555(98)80120-9","DOI":"10.1016\/S0936-6555(98)80120-9"},{"key":"1871_CR26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/106689690501300203","volume":"13","author":"R Montironi","year":"2005","unstructured":"Montironi R, Lopez-Beltran A (2005) The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol 13:143\u2013153","journal-title":"Int J Surg Pathol"},{"key":"1871_CR27","doi-asserted-by":"crossref","unstructured":"Chromecki T, Bensalah K, Remzi M, Verhoest G, Cha EK (2011) Prognostic factors for upper urinary tract urothelial carcinoma. PubMed\u2013NCBI. Nat Rev Urol 440\u2013447. http:\/\/www-ncbi-nlm-nih-gov.offcampus.dam.unito.it\/pubmed\/21727942 . Accessed 5 Apr 2016","DOI":"10.1038\/nrurol.2011.96"},{"key":"1871_CR28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.eururo.2009.11.035","volume":"57","author":"R Zigeuner","year":"2010","unstructured":"Zigeuner R, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Weizer A et al (2010) Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol 57:575\u2013581. doi: 10.1016\/j.eururo.2009.11.035","journal-title":"Eur Urol"},{"key":"1871_CR29","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/j.1464-410X.2010.09217.x","volume":"105","author":"SF Shariat","year":"2010","unstructured":"Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U et al (2010) International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 105:1402\u20131412. doi: 10.1111\/j.1464-410X.2010.09217.x","journal-title":"BJU Int"},{"key":"1871_CR30","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1016\/j.ejca.2013.02.001","volume":"49","author":"E Xylinas","year":"2013","unstructured":"Xylinas E, Rink M, Robinson BD, Lotan Y, Babjuk M, Brisuda A et al (2013) Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer 49:1889\u20131897. doi: 10.1016\/j.ejca.2013.02.001","journal-title":"Eur J Cancer"},{"key":"1871_CR31","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.eururo.2011.12.055","volume":"61","author":"M Rink","year":"2012","unstructured":"Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK et al (2012) Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 61:854\u2013855. doi: 10.1016\/j.eururo.2011.12.055","journal-title":"Eur Urol"},{"key":"1871_CR32","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/PAI.0b013e318241cab9","volume":"20","author":"M Vershasselt-Crinquette","year":"2012","unstructured":"Vershasselt-Crinquette M, Colin P, Ouzzane A, Gnemmi V, Robin Y-M, Aubert S et al (2012) Assessment of human epidermal growth factor receptor 2 status in urothelial carcinoma of the upper urinary tract: a study using dual-color in situ hybridization and immunohistochemistry. Appl Immunohistochem Mol Morphol 20:363\u2013366. doi: 10.1097\/PAI.0b013e318241cab9","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"1871_CR33","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)61094-6","volume":"382","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM et al (2013) 2\u00a0years versus 1\u00a0year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet (London, England) 382:1021\u20131028. doi: 10.1016\/S0140-6736(13)61094-6","journal-title":"Lancet (London, England)"},{"key":"1871_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00345-012-0947-5","volume":"31","author":"E Xylinas","year":"2013","unstructured":"Xylinas E, Kluth L, Mangal S, Roupret M, Karakiewicz PI, Shariat SF (2013) Predictive tools for clinical decision-making and counseling of patients with upper tract urothelial carcinoma. World J Urol 31:31\u201336. doi: 10.1007\/s00345-012-0947-5","journal-title":"World J Urol"},{"key":"1871_CR35","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.eururo.2007.09.036","volume":"52","author":"K Bensalah","year":"2007","unstructured":"Bensalah K, Montorsi F, Shariat SF (2007) Challenges of cancer biomarker profiling. Eur Urol 52:1601\u20131609. doi: 10.1016\/j.eururo.2007.09.036","journal-title":"Eur Urol"},{"key":"1871_CR36","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1002\/cncr.26172","volume":"117","author":"M Vassilakopoulou","year":"2011","unstructured":"Vassilakopoulou M, de la Motte Rouge T, Colin P, Ouzzane A, Khayat D, Dimopoulos M-A et al (2011) Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. Cancer 117:5500\u20135508. doi: 10.1002\/cncr.26172","journal-title":"Cancer"},{"key":"1871_CR37","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.eururo.2014.03.003","volume":"66","author":"JJ Leow","year":"2014","unstructured":"Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J (2014) A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 66:529\u2013541. doi: 10.1016\/j.eururo.2014.03.003","journal-title":"Eur Urol"},{"key":"1871_CR38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1464-410X.2012.11649.x","volume":"112","author":"E Xylinas","year":"2013","unstructured":"Xylinas E, Rink M, Margulis V, Clozel T, Lee RK, Comploj E et al (2013) Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. BJU Int 112:453\u2013461. doi: 10.1111\/j.1464-410X.2012.11649.x","journal-title":"BJU Int"},{"key":"1871_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2014.10.009","volume":"51","author":"S Oudard","year":"2015","unstructured":"Oudard S, Culine S, Vano Y, Goldwasser F, Th\u00e9odore C, Nguyen T et al (2015) Multicentre randomised phase II trial of gemcitabine\u00a0+\u00a0platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. Eur J Cancer 51:45\u201354. doi: 10.1016\/j.ejca.2014.10.009","journal-title":"Eur J Cancer"},{"key":"1871_CR40","doi-asserted-by":"publisher","DOI":"10.1159\/000443280","author":"F Wezel","year":"2016","unstructured":"Wezel F, Erben P, Gaiser T, Budjan J, von Hardenberg J, Michel MS et al (2016) Complete and durable remission of human epidermal growth factor receptor 2-positive metastatic urothelial carcinoma following third-line treatment with trastuzumab and gemcitabine. Urol Int. doi: 10.1159\/000443280","journal-title":"Urol Int"},{"key":"1871_CR41","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.juro.2012.05.079","volume":"189","author":"DA Green","year":"2013","unstructured":"Green DA, Rink M, Xylinas E, Matin SF, Stenzl A, Roupret M et al (2013) Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol 189:1214\u20131221. doi: 10.1016\/j.juro.2012.05.079","journal-title":"J Urol"},{"key":"1871_CR42","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1245\/s10434-012-2499-8","volume":"19","author":"M Rink","year":"2012","unstructured":"Rink M, Sjoberg D, Comploj E, Margulis V, Xylinas E, Lee RK et al (2012) Risk of cancer-specific mortality following recurrence after radical nephroureterectomy. Ann Surg Oncol 19:4337\u20134344. doi: 10.1245\/s10434-012-2499-8","journal-title":"Ann Surg Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-016-1871-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-016-1871-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-016-1871-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-016-1871-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T11:54:09Z","timestamp":1498305249000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-016-1871-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,7]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["1871"],"URL":"https:\/\/doi.org\/10.1007\/s00345-016-1871-x","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,7]]}}}